Annovis Bio Strengthens Research Team with Appointment of Biostatistics Director

Annovis Bio Inc., a neurodegenerative disease research company, has appointed Hui Liu as its new Director of Biostatistics, a strategic move designed to bolster the scientific rigor of its ongoing clinical research. Liu's extensive background, spanning nearly two decades in clinical trial design and analysis, represents a significant addition to the company's research infrastructure.

With over 19 years of professional experience across multiple therapeutic areas, Liu is expected to play a critical role in advancing Annovis Bio's pivotal Phase 3 Alzheimer's disease trial. Her expertise will be instrumental in ensuring the scientific integrity of the company's research data and refining regulatory submission strategies.

The appointment comes at a crucial time for Annovis Bio, which is focused on developing innovative therapies targeting neurodegenerative disorders. By bringing in a seasoned biostatistics professional, the company demonstrates its commitment to maintaining the highest standards of scientific research and analysis in its pursuit of transformative neurological treatments.

Liu's contributions are anticipated to be particularly significant in supporting the company's core mission of developing therapies that can potentially restore brain function and improve patient quality of life. Her skills in clinical trial design and data analysis will be essential in navigating the complex landscape of neurodegenerative disease research.

This strategic hiring underscores Annovis Bio's dedication to advancing scientific understanding and developing potential breakthrough treatments for challenging neurological conditions like Alzheimer's and Parkinson's diseases. The addition of Liu to the research team represents a forward-looking approach to addressing some of the most pressing medical challenges in neurodegenerative research.